Search research articles
Contact Us
Filters
Showing results (1-10 of 499) with videos related to
Page
of 50
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2006
Progress with biological agents in metastatic colorectal cancer leads to many challenges
Eric Van Cutsem
Clinical Advances in Hematology & Oncology : H&O
|
November 6, 2007
Integration of the anti-EGFR agent panitumumab into clinical practice in metastatic colorectal cancer
Eric Van Cutsem
Clinical Colorectal Cancer
|
December 6, 2007
Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer
Eric Van Cutsem
Future Oncology (London, England)
|
November 26, 2025
Trastuzumab deruxtecan in HER2-positive stomach or gastroesophageal junction cancer: a plain language summary of the DESTINY-Gastric02 study
Eric Van Cutsem
The Oncologist
|
October 13, 2006
Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer
Eric Van Cutsem
The Oncologist
|
May 27, 2004
The treatment of advanced gastric cancer: new findings on the activity of the taxanes
Eric Van Cutsem
Nature Clinical Practice. Gastroenterology & Hepatology
|
November 3, 2005
Can the addition of bevacizumab to IFL chemotherapy improve outcome in colorectal cancer?
Eric Van Cutsem
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society
|
January 27, 2006
The causes and consequences of cancer-associated malnutrition
Eric Van Cutsem, Jann Arends
Lancet (London, England)
|
May 7, 2013
Regorafenib for metastatic colorectal cancer - Authors' reply
Eric Van Cutsem, Axel Grothey
JAMA
|
December 8, 2005
Progress in the adjuvant treatment of colon cancer: has it influenced clinical practice?
Eric Van Cutsem, Frederico Costa
Page
of 50
Search research articles
Search
Showing results (1-10 of 499) with videos related to
Sort By:
Page
of 50
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2006
Progress with biological agents in metastatic colorectal cancer leads to many challenges
Eric Van Cutsem
Clinical Advances in Hematology & Oncology : H&O
|
November 6, 2007
Integration of the anti-EGFR agent panitumumab into clinical practice in metastatic colorectal cancer
Eric Van Cutsem
Clinical Colorectal Cancer
|
December 6, 2007
Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer
Eric Van Cutsem
Future Oncology (London, England)
|
November 26, 2025
Trastuzumab deruxtecan in HER2-positive stomach or gastroesophageal junction cancer: a plain language summary of the DESTINY-Gastric02 study
Eric Van Cutsem
The Oncologist
|
October 13, 2006
Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer
Eric Van Cutsem
The Oncologist
|
May 27, 2004
The treatment of advanced gastric cancer: new findings on the activity of the taxanes
Eric Van Cutsem
Nature Clinical Practice. Gastroenterology & Hepatology
|
November 3, 2005
Can the addition of bevacizumab to IFL chemotherapy improve outcome in colorectal cancer?
Eric Van Cutsem
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society
|
January 27, 2006
The causes and consequences of cancer-associated malnutrition
Eric Van Cutsem, Jann Arends
Lancet (London, England)
|
May 7, 2013
Regorafenib for metastatic colorectal cancer - Authors' reply
Eric Van Cutsem, Axel Grothey
JAMA
|
December 8, 2005
Progress in the adjuvant treatment of colon cancer: has it influenced clinical practice?
Eric Van Cutsem, Frederico Costa
Page
of 50